New scan could reveal breast cancer type without a needle

NCT ID NCT05923177

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a new radioactive imaging agent, called [123I] I-(HE)3-G3, to see if it can safely detect HER2 protein in breast cancer tumors using SPECT scans. Ten people with either HER2-positive or HER2-negative breast cancer received one injection and were scanned over 48 hours. The goal was to measure how the agent spreads in the body and whether it can tell HER2-positive from HER2-negative tumors, potentially offering a non-invasive way to determine cancer type.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodine-123-labelled designed ankyrin repeat proteins HE3-G3 ([123I] I-(HE)3-G3)
What this could lead to: If successful, this could lead to a new imaging method to see HER2 status in breast cancer without needing a biopsy.
What could go wrong: This is a very early, small Phase 1 study with only 10 people. It only tests if the imaging agent is safe and can be seen on scans, not if it improves outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BREAST CANCER

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.